Uveitis
Conditions
Brief summary
This project is designed to test the hypothesis that acyclovir is clinically useful for patients with refractory viral uveitis.
Detailed description
Approval of the study was obtained from the hospital's ethical committee. The study design and methodology followed the tenets of Declaration of Helsinki. All patients were provided with written informed consent and received a thorough explanation of the study design, aims, benefits and potential risks. This is a prospective non-comparative interventional study. Aqueous humor samples were collected from participants to virus detection. Participants will take oral acyclovir 100 mg three times a day and data will be collected prospectively with regard to ophthalmologic outcomes. Study participants will be followed for up to 12 months to determine efficacy, and an additional 30 days for safety reports. Descriptive statistics will be gathered on participant demographics, uveitis characteristics, change in immunosuppressive medications, number of responders, ophthalmologic measures and change in corticosteroid dose during the study period.
Interventions
DRUGAcyclovir
Sponsors
Xiaomin Zhang
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age between 18 and above. * Chronic, vision threatening viral uveitis. * Patients can't tolerate hormone therapy bacause of drug side effects. * Consent to undergo anterior chamber tap and give aqueous for the study. * Able to undergo relevant tests. * Able to come for subsequent follow-up visits. * Ability to provide informed consent.
Exclusion criteria
* Patients who are allergic to ayclovir. * Immunocompromised patients * Positive for HIV, Hep B and Hep C * Not keen on participating in the study * Patients who are incapable, either by law or mental state, of giving consents in their own right. * Patients who are either unable or unwilling to keep scheduled appointments and adhere to the other aspects of the protocol. * Patients who are pregnant or breastfeeding. * Any other specified reason as determined by the clinical investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean and median change in best corrected visual acuity in logMAR | 12 weeks | Mean and median change in best corrected visual acuity in logMAR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants who experience a recurrence | 12 weeks | Number of participants who experience a recurrence |
| Length of time to quiescence | 12 weeks | Length of time to quiescence |
| Ability to taper concomitant immunosuppressive medications | 12 weeks | Ability to taper concomitant immunosuppressive medications |
| Number and severity of systemic and ocular toxicities and adverse events | 12 weeks | Number and severity of systemic and ocular toxicities and adverse events |
Countries
China
Contacts
Primary ContactXiaomin Zhang, M.D.
Backup ContactJing Yang
Outcome results
None listed